Mycobacterium chimaera: a case report from Italy

Submitted: January 27, 2024
Accepted: July 23, 2024
Published: September 13, 2024
Abstract Views: 83
PDF_EARLY VIEW: 51
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Mycobacterium chimaera is an environmental non-tuberculous mycobacterium belonging to Mycobacterium avium complex (MAC). It has been widely known to be associated with disseminated infection after cardiac surgery, related to heater-cooler units used during these procedures. Although M. chimaera seems to be a less virulent species compared to M. avium and M. intracellulare among MAC, several cases of M. Chimaera lung infections have been reported in settings of chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, malignancy, or immunosuppression. Here, we present an Italian case report in association with newly diagnosed COPD.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Tortoli E, Rindi L, Garcia MJ, et al. Proposal to elevate the genetic variant MAC-A included in the Mycobacterium avium complex, to species rank as Mycobacterium chimaera sp. nov. Int J Syst Evol Microbiol 2004;54:1277-85. DOI: https://doi.org/10.1099/ijs.0.02777-0
Wetzstein N, Kohl TA, Diricks M, et al. Clinical characteristics and outcome of Mycobacterium chimaera infections after cardiac surgery: systematic review and meta-analysis of 180 heater-cooler unit-associated cases. Clin Microbiol Infect 2023;29:1008-14. DOI: https://doi.org/10.1016/j.cmi.2023.03.005
Chiesi S, Piacentini D, Salerno ND, et al. Disseminated Mycobacterium chimaera infection after open heart surgery in an Italian woman: a case report and a review of the literature. Infez Med 2017;3:267-9.
Larcher R, Lounnas M, Dumont Y, et al. Mycobacterium chimaera pulmonary disease in cystic fibrosis patients, France, 2010-2017. Emerg Infect Dis 2019;25:611-3. DOI: https://doi.org/10.3201/eid2503.181590
Miskoff JA, Chaudhri M. Mycobacterium Chimaera: a rare presentation. Cureus 2018;10:e2750. DOI: https://doi.org/10.7759/cureus.2750
Robinson B, Chaudhri M, Miskoff JA. A case of cavitary Mycobacterium chimaera. Cureus 2022;14:e26984. DOI: https://doi.org/10.7759/cureus.26984
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Report 2023.
Daley CL, Iaccarino JM, Lange C, et al. Treatment of non-tuberculous mycobacterial pulmonary disease: An official ats/ers/escmid/idsa clinical practice guideline. Clin Infect Dis 2020;71:e1-36. DOI: https://doi.org/10.1093/cid/ciaa241
Suska K, Amati F, Sotgiu G, et al. Non-tuberculous mycobacteria infection and pulmonary disease in bronchiectasis. ERJ Open Res 2022;8:00060-2022. DOI: https://doi.org/10.1183/23120541.00060-2022
Sommerstein R, Rüegg C, Kohler P, et al. Transmission of Mycobacterium chimaera from heater-cooler units during cardiac surgery despite an ultraclean air ventilation system. Emerg Infect Dis 2016;22:1008-13. DOI: https://doi.org/10.3201/eid2206.160045
Bills ND, Hinrichs SH, Aden TA, et al. Molecular identification of Mycobacterium chimaera as a cause of infection in a patient with chronic obstructive pulmonary disease. Diagn Microbiol Infect Dis 2009;63:292-5. DOI: https://doi.org/10.1016/j.diagmicrobio.2008.12.002
Azzarà C, Lombardi A, Gramegna A, et al. Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera in a 67-year-old man treated with immune checkpoint inhibitors for lung adenocarcinoma: infection due to dysregulated immunity?. BMC Infect Dis 2023;23:573. DOI: https://doi.org/10.1186/s12879-023-08537-w
Loebinger MR, Quint JK, van der Laan R, et al. Risk Factors for Non-tuberculous mycobacterial pulmonary disease: a systematic literature review and meta-analysis. Chest 2023;164:1115-24. DOI: https://doi.org/10.1016/j.chest.2023.06.014
Sharma S, Upadhyay V. Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases. Indian J Med Res 2020;152:185-226. DOI: https://doi.org/10.4103/ijmr.IJMR_902_20
O’Neill K, O’Donnell AE, Bradley JM. Airway clearance, mucoactive therapies and pulmonary rehabilitation in bronchiectasis. Respirology 2019;24:227-37. DOI: https://doi.org/10.1111/resp.13459
Spruit MA, Singh SJ, Garvey C, et al. An official American thoracic society/European respiratory society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013;188:e13-64. DOI: https://doi.org/10.1164/rccm.201308-1509ST
Faverio P, De Giacomi F, Bodini BD, et al. Non-tuberculous mycobacterial pulmonary disease: An integrated approach beyond antibiotics. ERJ Open Res 2021;7:00574-2020. DOI: https://doi.org/10.1183/23120541.00574-2020
Ni S, Chen Y, Hu B, Yuan Z. Anxiety and depression among patients with non-tuberculous mycobacterial disease in Shanghai: a cross-sectional study. Front Psychiatry 2023;14:1132675. DOI: https://doi.org/10.3389/fpsyt.2023.1132675
Youssefnia A, Pierre A, Hoder JM, et al. Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review. J Thorac Dis 2022;14:3575-97. DOI: https://doi.org/10.21037/jtd-22-410
Omatsu S, Tabusadani M, Yamane K, et al. Clinical significance and safety of combined treatment with chemotherapy and pulmonary rehabilitation regarding health-related quality of life and physical function in non-tuberculous mycobacterial pulmonary disease. Respir Investig 2022;60:674-83. DOI: https://doi.org/10.1016/j.resinv.2022.06.006

How to Cite

Seminara, Martina Maria, Dina Visca, Alice Claudia Repossi, and Antonio Spanevello. 2024. “<i>Mycobacterium chimaera</i>: A Case Report from Italy”. Monaldi Archives for Chest Disease, September. https://doi.org/10.4081/monaldi.2024.2933.